ETFs Investing in Altimmune, Inc. Stocks
This article lists various ETFs that hold Altimmune, Inc. (0A4C) stocks, providing detailed information about each fund. The data includes market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and NAV total return over three years. The purpose is to demonstrate how these ETFs can offer more accessible and lower-risk investment opportunities in stocks like Altimmune.
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark
Altimmune, Inc. (NasdaqGM:ALT) has been removed from the Russell Small Cap Comp Growth Benchmark. This news comes amidst other recent updates for the biopharmaceutical company, including presentations at a healthcare conference and data releases on its lead product candidate, pemvidutide, for treating liver diseases. The company is in late clinical-stage development, focusing on novel therapies for conditions like metabolic dysfunction-associated steatohepatitis (MASH).
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark
Altimmune, Inc. (NasdaqGM: ALT), a late clinical-stage biopharmaceutical company focused on liver disease therapies, has been removed from the Russell 2500 Growth Benchmark. The company's lead product candidate, pemvidutide, is in development for conditions such as MASH, AUD, and ALD. Analysts currently have a "BUY" consensus rating for Altimmune, with an average target price significantly higher than its last closing price.
Altimmune, Inc.(NasdaqGM: ALT) added to Russell Microcap Value Benchmark Index
Altimmune, Inc. (NasdaqGM: ALT) has been added to the Russell Microcap Value Benchmark Index. This announcement was made on June 29, 2026, and is significant for the late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases, including its lead product candidate, pemvidutide.
Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Growth Benchmark
Altimmune, Inc. (NasdaqGM: ALT), a late clinical-stage biopharmaceutical company focusing on liver diseases, has been removed from the Russell 2000 Growth Benchmark. Despite this drop, the company continues to develop its lead product candidate, pemvidutide, for treatments like metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-associated liver disease, having recently presented positive data from its Phase 2b trial. Analysts maintain a "BUY" consensus for Altimmune, with an average target price significantly above its current trading price.
ALT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Altimmune, Inc. (NASDAQ: ALT) for alleged federal securities law violations. The lawsuit claims Altimmune made false and misleading statements regarding its Pemvidutide MASH trial and downplayed its failure to meet statistical significance. Investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, are encouraged to join the case and may request to be appointed as lead plaintiff by October 6, 2025.
Enterprise value to revenue forward of Altimmune, Inc. – NASDAQ:ALT
This article focuses on the enterprise value to revenue forward for Altimmune, Inc. (NASDAQ:ALT). It is likely a financial data point or metric provided by TradingView, indicating a key valuation measure for the biotechnology company. The content appears to be a stub or data-focused page rather than a detailed analytical article.
Price to book forward of Altimmune, Inc. – SWB:3G0
This article provides financial information for Altimmune, Inc. (SWB:3G0), specifically focusing on its price-to-book forward ratio. The content appears to be a stub or a section of a larger financial data report, indicating that the value for this metric is available for different periods.
Enterprise value to revenue forward of Altimmune, Inc. – SWB:3G0
The provided content is a financial data page for Altimmune, Inc. (SWB:3G0) on TradingView, focusing on its enterprise value to revenue forward metric. The page includes general company information, market data from the Stuttgart Stock Exchange, and various navigation elements common to the TradingView platform.
Enterprise value to EBIT forward of Altimmune, Inc. – NASDAQ:ALT
This page provides financial information for Altimmune, Inc. (NASDAQ: ALT), focusing on its enterprise value to EBIT forward. It indicates that the market was closed with no trades, and the content primarily serves as a data display from TradingView sourced from ICE Data Services, FactSet, and Quartr for SEC filings.
Price to sales forward of Altimmune, Inc. – NASDAQ:ALT
This article provides the "Price to sales forward" financial metric for Altimmune, Inc. (NASDAQ: ALT). It appears to be a stub or a section of a larger financial data report, indicating the value and change of this specific financial ratio for the company. The content primarily focuses on the financial data point without providing further analysis or discussion.
Price to earnings forward of Altimmune, Inc. – SWB:3G0
This article provides financial information for Altimmune, Inc. (SWB:3G0) on TradingView, specifically focusing on its forward price-to-earnings ratio. It highlights that the market was closed and no trades were made at the time of publication, indicating a static financial snapshot. The content is primarily a listing of navigation and data sourcing information rather than an analytical piece.
Price to earnings forward of Altimmune, Inc. – BMV:ALT1
This article focuses on the "Price to earnings forward" metric for Altimmune, Inc. (BMV:ALT1). The content includes financial overview elements and market data references. It appears to be a stub or a section from a larger financial analysis platform.
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
The drug and biotech sector is recovering from a difficult period, driven by strong M&A activity, pipeline successes, and innovation. The Zacks Medical-Drugs industry, which includes small and medium-sized drug companies, shows promising trends, with Indivior Pharmaceuticals, Aurinia Pharmaceuticals, Ironwood Pharmaceuticals, Altimmune, and Marker Therapeutics highlighted as potential investment opportunities. Despite challenges like pipeline setbacks and regulatory uncertainty, the sector's growth is supported by accelerating innovation, AI in drug discovery, and positive clinical developments.
Enterprise value to EBITDA forward of Altimmune, Inc. – BMV:ALT1
This article displays financial data, specifically the Enterprise Value to EBITDA forward, for Altimmune, Inc. (BMV:ALT1). It indicates that the market for this stock was closed with no trades recorded. The content is presented within the TradingView platform interface, emphasizing financial metrics for the biotechnology company.
A2N5Z6 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Altimmune, Inc. (A2N5Z6) stock, including analyst price targets and ratings. It details recent stock performance, future earnings expectations, and various financial metrics for the company. The current price is 2.6000 EUR, with a 1-year price forecast ranging from 2.18 EUR to 24.44 EUR.
Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?
Altimmune, Inc. (NASDAQ:ALT) remains a "Buy" according to H.C. Wainwright, despite a price target reduction from $25 to $20 due to dilution from recent equity offerings. The company's strengthened funding position and progress in its MASH program are viewed positively. Recent Phase 2b trial results for pemvidutide showed significant improvements in cardiometabolic measures and a favorable safety profile for patients with metabolic dysfunction-associated steatohepatitis (MASH).
Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Altimmune Inc (ALT) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have a consensus "Buy" rating for ALT, with an average price target of $20.00 and a potential upside of 543.13%. The company's expected revenue for the next quarter is $1.75K, and the EPS was -$0.26 for the last quarter, with an expectation of -$0.16 for the next.
Altimmune Relocates Corporate Headquarters to Morristown, New Jersey
Altimmune, Inc. announced its decision to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year, signing a five-year lease. This strategic move aims to leverage Morristown's dense biopharmaceutical industry presence, enhance talent recruitment, and achieve long-term cost efficiencies. The relocation aligns with Altimmune's hybrid work model and expansion plans, strengthening its competitive position in the biopharmaceutical sector.
Altimmune moving headquarters from Gaithersburg to New Jersey
Altimmune is relocating its headquarters from Gaithersburg, Maryland, to New Jersey, citing cost efficiencies and better access to top-tier talent
Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic Data
Altimmune (NASDAQ:ALT) is advancing its lead drug candidate, pemvidutide, for MASH, a serious liver disease. Recent 48-week data from its IMPACT Phase 2b study showed improvements in metabolic health measures, including triglycerides and cholesterol, and the company plans to start a larger Phase 3 trial in late 2026. Altimmune also has a strong cash position and is exploring pemvidutide for alcohol use disorder.
Altimmune Relocating Headquarters from Maryland to New Jersey
Altimmune, Inc. (NASDAQ: ALT) is moving its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year. This strategic relocation aims to enhance access to biopharmaceutical talent and improve operational efficiencies, positioning the company within a major biopharma hub. The move supports Altimmune's growth strategy as it advances its clinical pipeline, including its lead candidate pemvidutide for metabolic disorders.
Altimmune Inc (ALT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Altimmune Inc's (ALT) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and provides no data on stock splits. The piece presents basic financial information for Altimmune, including its market capitalization and current stock price.
Altimmune (ALT) plans New Jersey HQ move with 5-year lease
Altimmune, Inc. (ALT) announced its plans to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year. The move to the new biopharmaceutical hub is expected to support talent recruitment and achieve long-term cost efficiencies. Altimmune has secured a five-year office lease for its New Jersey headquarters, with annual rent payments of approximately $300,000.
5 Small Cap Stocks with Potential to Rise 1000 Percent
This article highlights Altimmune, Inc. (NASDAQ:ALT) as one of five small-cap stocks with significant growth potential, possibly rising 1000 percent. Altimmune is a late-clinical stage biotechnology company developing pemvidutide for serious liver diseases like MASH, alcohol use disorder, and alcohol-associated liver disease. The company has strong balance sheets and expects to move pemvidutide into a larger Phase 3 MASH trial in the latter half of 2026, with data from other trials expected later in the same year.
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near
Altimmune management outlined their strategy for pemvidutide, their lead metabolic and liver disease drug candidate, at the Goldman Sachs Global Healthcare Conference. The company is primarily focusing on pemvidutide's Phase 3 program for metabolic dysfunction-associated steatohepatitis (MASH), leveraging its unique GLP-1 and glucagon activity for liver disease. Additionally, Altimmune is awaiting Phase 2 data for pemvidutide in alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), with a goal to begin patient enrollment for the Phase 3 MASH trial in the second half of the year.
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near
Altimmune is preparing for Phase 3 trials of its drug candidate, pemvidutide, for metabolic dysfunction-associated steatohepatitis (MASH), emphasizing its dual GLP-1/glucagon mechanism and financial readiness. The company plans to test 1.8 mg and 2.4 mg doses, with an interim histology readout after 52 weeks for potential accelerated approval, and expects data in alcohol use disorder (AUD) next quarter. Altimmune views AUD and alcohol-associated liver disease (ALD) as additional development avenues that could be pursued with non-dilutive financing or partnerships if the data are supportive.
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
Altimmune (ALT) is focusing its investment strategy on pemvidutide, a single clinical asset with potential applications in various liver diseases like MASH, AUD, and ALD. The company aims to leverage clinical milestones and sufficient capital to advance pemvidutide through late-stage trials, including a global Phase III study for MASH expected to begin in H2 2026. This strategy, backed by FDA designations and promising mid-stage data, positions pemvidutide as a significant growth driver, although execution risk remains given the company's reliance on this single drug.
Altimmune Shares Drop After $225 Million Offering Prices
Altimmune's shares experienced a significant drop after the pricing of its upsized underwritten public offering of common stock and pre-funded warrants. The offering aimed to raise $225 million in gross proceeds, with the company offering over 27.5 million shares and pre-funded warrants at $8.15 per share. The net proceeds are intended to fund clinical development, manufacturing, and other general corporate purposes.
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
Altimmune (ALT) is positioned for a catalyst-heavy 2026 driven by its lead clinical asset, pemvidutide, with key milestones including the planned start of a global Phase III study for metabolic dysfunction-associated steatohepatitis and top-line Phase II data for alcohol use disorder. The company's financial position is strong, with a cash runway expected into 2029, though significant competition and pre-revenue status present both opportunities for outsized gains and risks. Investors will be closely watching execution in these pivotal programs, as the company's valuation is heavily tied to pemvidutide's success across its multiple indications.
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns
Altimmune Inc. (ALT) shares dropped 9% after the company reported a wider-than-expected Q4 loss of $0.27 per share, exceeding Wall Street estimates. Despite the loss, Altimmune confirmed it has $340 million in cash, sufficient to fund operations into 2028, and is strategically pursuing capital for its late-stage MASH trial. Retail investors on Stocktwits expressed disappointment but also hopes for a potential buyout or partnership deal, emphasizing the company's long-term strategy.
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff?
Lululemon (LULU), Lucid Group (LCID), and Altimmune (ALT) stocks plummeted to 52-week lows due to concerns over leadership uncertainty, financial instability, and strategic direction. Lululemon's decline was driven by a delayed CEO transition and weak North American sales, while Lucid faced investor skepticism over ongoing losses despite new funding. Altimmune's stock fell following an announcement of a $225 million stock offering to fund its Phase 3 MASH trial, leading to dilution fears.
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
Altimmune (NASDAQ:ALT) is preparing to initiate patient enrollment for a Phase 3 trial of its drug pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) in the second half of the year. The company highlighted recent positive data presented at the European Association for the Study of the Liver (EASL) meeting, reinforcing pemvidutide's potential differentiation in the competitive MASH market and its strong anti-fibrotic effects. Altimmune also awaits data from related alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) programs, with the company's robust balance sheet expected to fund operations through MASH trial results in 2029.
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
Altimmune is preparing to begin Phase 3 patient enrollment for its pemvidutide MASH trial in the second half of the year, following positive data presentations. The company emphasizes pemvidutide's differentiation with a dual mechanism and good tolerability, and has secured over $500 million in funding to support operations through the 2029 MASH results. Altimmune is also anticipating data from its alcohol use disorder and alcohol-associated liver disease programs in the third quarter.
ALT: Pemvidutide's phase III MASH trial advances with strong data, funding, and regulatory alignment
Altimmune, Inc. (ALT) is moving forward with Phase III enrollment for its drug pemvidutide in treating MASH, anticipated later this year. This progress is backed by strong data from EASL, robust funding, and a strategy that utilizes AI tools and flexible endpoints, aiming for a distinct position in the competitive market. The company also expects to release Phase II AUD data soon.
Altimmune (NasdaqGM:ALT) Stock Forecast & Analyst Predictions
Altimmune (ALT) stock is analyzed with a focus on future growth prospects and recent significant announcements. Analysts forecast revenue growth at 74.2% per year, but earnings are expected to decline by 9.7% annually. The company's lead drug candidate, pemvidutide, has received FDA Breakthrough Therapy Designation for MASH and Fast Track designations for MASH and Alcohol Use Disorder (AUD), with ongoing clinical trials.
Altimmune, Inc. to Participate in Upcoming Investor Conferences in June 2026
Altimmune, Inc. announced its management will participate in two investor conferences in June 2026 to discuss its lead drug candidate, pemvidutide, for serious liver diseases. These events include the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference, both featuring web-accessible fireside chats. The company's lead candidate, pemvidutide, is a dual-action therapy targeting glucagon and GLP-1 receptors, currently in development for conditions like MASH, AUD, and ALD.
Altimmune reports 48-week pemvidutide trial results at EASL
Altimmune Inc. presented positive 48-week data from its IMPACT Phase 2b trial for pemvidutide, showing significant reductions in triglycerides, cholesterol, and improvements in other metabolic markers for patients with MASH. The stock rose 6% on the news, with analysts maintaining bullish price targets and highlighting the company's strong financial position. Altimmune plans to initiate its Phase 3 trial in the second half of 2026, building on previous positive results and Fast Track designations.
Liver disease trial: pemvidutide lowers fats, weight and blood pressure
Altimmune's pemvidutide, a MASH drug candidate, demonstrated significant improvements in metabolic risk factors over 48 weeks, reducing triglycerides by 23.7%, total cholesterol by 15.4%, and weight by 7.5% in patients with metabolic dysfunction-associated steatohepatitis (MASH). The drug also lowered BMI, waist circumference, and blood pressure, with a favorable safety profile and approximately 1% discontinuation due to adverse events. These positive Phase 2b results support the planned initiation of the PERFORMA Phase 3 trial later this year.
Altimmune schedules June investor fireside chats in New York and Miami
Altimmune (Nasdaq: ALT) announced its participation in two upcoming healthcare investor conferences in June 2026. Management will hold fireside chats at the Jefferies Global Healthcare Conference in New York on June 4 and the Goldman Sachs Global Healthcare Conference in Miami Beach on June 10. Webcasts of these sessions will be available on Altimmune's website for investors interested in updates on their lead investigational candidate, pemvidutide, for serious liver diseases.
Altimmune to Participate in Upcoming Investor Conferences
Altimmune, Inc. (Nasdaq: ALT) announced that its management will participate in two upcoming investor conferences: the 2026 Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, a late clinical-stage biopharmaceutical firm, is developing pemvidutide for serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Webcasts of the fireside chats from these events will be available on the Altimmune website.
Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease
Altimmune's Phase 2b trial data for pemvidutide, a GLP-1/glucagon dual receptor agonist, showed significant improvements in liver disease metrics. The trial indicated a high proportion of patients achieved NASH resolution and fibrosis improvement, with positive implications for patients with metabolic dysfunction-associated steatohepatitis (MASH). These results position pemvidutide as a promising candidate for MASH treatment.
Altimmune to Participate in Upcoming Investor Conferences
This article announces that Altimmune will be participating in upcoming investor conferences. It is an invitation for investors to attend or listen to the presentations.
AI imaging tracks fibrosis regression in Altimmune MASH study
Altimmune announced new Phase 2b data for its drug pemvidutide in MASH, presented at EASL 2026. The results highlighted concurrent improvements across multiple non-invasive disease markers and significant fibrosis regression, as measured by AI-based qFibrosis digital pathology, after 24 weeks of treatment. The company plans to initiate its PERFORMA Phase 3 MASH trial in the second half of the year based on these promising findings.
Altimmune reports positive pemvidutide trial data for MASH
Altimmune Inc. announced positive new analyses from its IMPACT Phase 2b trial for pemvidutide, showing improvements in non-invasive tests for metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. The data, presented at a European liver congress, indicated significant fibrosis regression and reduction in liver stiffness for patients treated with pemvidutide compared to placebo. The company plans to initiate its PERFORMA Phase 3 trial for MASH in the latter half of the year, while analysts have adjusted price targets due to recent capital raises.
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
Altimmune (ALT), a late clinical-stage biotech company specializing in liver disease therapies, is highlighted as a strong buy due to its lead candidate, pemvidutide. This drug targets the multi-billion-dollar MASH market and has shown promising results in clinical trials, securing Fast Track and Breakthrough Therapy designations. The company also has expansion plans for pemvidutide into alcohol-related liver diseases, with key data readouts expected in 2026.
Altimmune Q3 2025 Earnings Preview
This article provides a brief earnings preview for Altimmune's Q3 2025 results. It mentions that the company is expected to announce its earnings.
Altimmune's Q1 loss narrower than expected, revenues nil
Altimmune announced a narrower-than-expected loss for the first quarter of 2026, with no revenues reported. This suggests the company is still in a developmental or pre-commercialization phase. Investors will be watching for future developments regarding their product pipeline and potential revenue generation.
Altimmune Q3 2025 Earnings Preview
This article provides a preview of Altimmune's Q3 2025 earnings. Further details are not available in the provided snippet.
H.C. Wainwright cuts Altimmune stock price target on dilution By Investing.com
H.C. Wainwright has reduced its price target for Altimmune (NASDAQ:ALT) stock from $25 to $20, while maintaining a Buy rating. This adjustment is due to share-count dilution resulting from capital raises in January and April. Despite the cut, the analyst consensus remains "Strong Buy," and Altimmune recently reported better-than-expected Q1 2026 earnings per share.
